33 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts https://www.zacks.com/stock/news/2242442/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2242442 Mar 18, 2024 - Johnson & Johnson (JNJ) closed the most recent trading day at $156.76, moving -0.9% from the previous trading session.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242244 Mar 18, 2024 - Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
Meet the "Magnificent Seven" Stock That Pays More Dividends Than Any Other U.S.-Based Company https://www.fool.com/investing/2024/03/16/magnificent-seven-stock-pays-most-dividends/?source=iedfolrf0000001 Mar 16, 2024 - Microsoft is the complete package.
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296 Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446 Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Top Stock Reports for UnitedHealth, Johnson & Johnson & Oracle https://www.zacks.com/commentary/2240062/top-stock-reports-for-unitedhealth-johnson-johnson-oracle?cid=CS-ZC-FT-research_daily-2240062 Mar 13, 2024 - Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Oracle Corporation (ORCL).
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322 Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues https://www.zacks.com/stock/news/2236717/bayer-bayry-q4-earnings-top-crop-science-unit-drives-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236717 Mar 06, 2024 - Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer https://www.zacks.com/stock/news/2235489/j-j-jnj-secures-full-fda-nod-for-rybrevant-in-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2235489 Mar 04, 2024 - The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts https://www.zacks.com/stock/news/2229635/johnson-johnson-jnj-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2229635 Feb 21, 2024 - In the most recent trading session, Johnson & Johnson (JNJ) closed at $158.68, indicating a +0.52% shift from the previous trading day.

Pages: 1234

Page 1>